

# WEST Search History

DATE: Tuesday, August 06, 2002

## Set Name Query

side by side

## Hit Count Set Name

result set

*DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*

L7 (Juniper\$(malt) and elastase not l6

2 L7

L6 (Juniper\$(malt) same elastase

1 L6

*DB=USPT; PLUR=YES; OP=ADJ*

L5 (Juniper\$(malt) same elastase

4 L5

L4 6375948.pn.

1 L4

L3 (almond|rose|clove|hawthorn|betula|gambir) same elastase

4 L3

L2 L1 same inhib\$

7 L2

L1 (almond|rose|clove|hawthorn|betula|gambir) same hair

305 L1

END OF SEARCH HISTORY

\*\*\*\*\*STN Columbus\*\*\*\*\*  
\*\*\*\*\*

FILE 'HOME' ENTERED AT 08:45:07 ON 06 AUG  
2002

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT  
AUTHORIZED

COST IN U.S. DOLLARS                      SINCE  
FILE    TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21    0.21

INDEX 'ADISALERTS, ADISINSIGHT,  
ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,  
      BIOBUSINESS, BIOCOMMERCE, BIOSIS,  
BIOTECHABS, BIOTECHDS, BIOTECHNO,  
CABA,  
      CANCERLIT, CAPLUS, CEABA-VTB, CEN,  
CIN, CONFSCI, CROPB, CROPU, DDFB,  
      DDFU, DGENE, DRUGB, DRUGLAUNCH,  
DRUGMONOG2, ...'  
ENTERED AT 08:45:32 ON 06 AUG 2002

63 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings  
or to view

search error messages that display as 0\* with SET  
DETAIL OFF.

=> s (almond or rose or clove or hawthorn or betula  
or gambir or juniper? or malt) (10a) (elastase (5a)  
inhib?)

2 FILE BIOSIS  
12 FILES SEARCHED...  
4 FILE CAPLUS  
24 FILES SEARCHED...  
2 FILE EMBASE  
39 FILES SEARCHED...  
1 FILE IFIPAT  
2 FILE MEDLINE  
50 FILES SEARCHED...

1 FILE SCISEARCH  
1 FILE TOXCENTER  
3 FILE USPATFULL  
61 FILES SEARCHED...  
3 FILE WPIDS  
3 FILE WPINDEX

10 FILES HAVE ONE OR MORE ANSWERS.  
63 FILES SEARCHED IN STNINDEX

L1 QUE (ALMOND OR ROSE OR CLOVE OR  
HAWTHORN OR BETULA OR GAMBIR OR  
JUNIPER? O  
      R MALT) (10A) (ELASTASE (5A) INHIB?)

=> d rank

F1     4 CAPLUS  
F2     3 USPATFULL  
F3     3 WPIDS  
F4     3 WPINDEX  
F5     2 BIOSIS  
F6     2 EMBASE  
F7     2 MEDLINE  
F8     1 IFIPAT  
F9     1 SCISEARCH  
F10    1 TOXCENTER

=> file f1 f3-10

COST IN U.S. DOLLARS                      SINCE  
FILE    TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.95    8.16

FILE 'CAPLUS' ENTERED AT 08:54:29 ON 06  
AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR  
STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR  
DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL  
SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 08:54:29 ON 06 AUG  
2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'BIOSIS' ENTERED AT 08:54:29 ON 06 AUG  
2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS  
INC.(R)

FILE 'EMBASE' ENTERED AT 08:54:29 ON 06  
AUG 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All  
rights reserved.

FILE 'MEDLINE' ENTERED AT 08:54:29 ON 06  
AUG 2002

FILE 'IFIPAT' ENTERED AT 08:54:29 ON 06 AUG  
2002

COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent  
Services (IFI)

FILE 'SCISEARCH' ENTERED AT 08:54:29 ON 06  
AUG 2002

COPYRIGHT (C) 2002 Institute for Scientific  
Information (ISI) (R)

FILE 'TOXCENTER' ENTERED AT 08:54:29 ON  
06 AUG 2002

COPYRIGHT (C) 2002 ACS

=> s l1

5 FILES SEARCHED...

L2 16 L1

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 11 DUP REM L2 (5 DUPLICATES  
REMOVED)

ANSWERS '1-4' FROM FILE CAPLUS  
ANSWERS '5-7' FROM FILE WPIDS  
ANSWERS '8-9' FROM FILE BIOSIS  
ANSWER '10' FROM FILE IFIPAT  
ANSWER '11' FROM FILE SCISEARCH

=> d bib abs 1-11

L3 ANSWER 1 OF 11 CAPLUS COPYRIGHT  
2002 ACS

AN 2000:271984 CAPLUS

DN 132:269859

TI Elastase inhibitors for cosmetics

IN Moriwaki, Shigeru; Tsuji, Shoko; Shibuya,  
Yusuke; Kusuoku, Hiroshi;

Kanazawa, Satoshi

PA Kao Corp., Japan

SO Jpn. Kokai Tokkyo Koho, 4 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO. KIND DATE

APPLICATION NO. DATE

PI JP 2000119189 A2 20000425 JP 1998-  
283981 19981006

JP 2969451 B2 19991102

AB This invention relates to an \*\*\*elastase\*\*\*

\*\*\*inhibitor\*\*\* which

includes steam distillates or pressed products of  
ginger rhizome,

\*\*\*almond\*\*\* hydrolyzates, Sanguisorba  
rhizome, Syzygium aromaticum,

Rosa multiflora fruit, Crataegus oxyantha, and  
Betula alba. The above

plant exts. at the concn. .ltoreq. 5 % evapn.  
residue equiv., show

.gtoreq. 25 % of elastase inhibitory activities

using N-succinyl-Ala-Ala-

Ala-p-nitroanilide substrate.

L3 ANSWER 2 OF 11 CAPLUS COPYRIGHT  
2002 ACS

AN 2000:252036 CAPLUS

DN 132:269854

TI Antiaging cosmetics containing plant extracts  
and soy proteins

IN Sugiyama, Hiromichi; Ohara, Yasuhiro; Sakai,  
Yuji

PA Pola Chemical Industries, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO. KIND DATE

APPLICATION NO. DATE

PI JP 2000109420 A2 20000418 JP 1998-  
297645 19981005

AB This invention relates to antiaging cosmetics  
comprising (1) elastase

inhibitors selected from the group consisting of  
soybean protein and

Engelhardtia chrysolepis exts. and (2) peroxide  
formation inhibitors

selected from the group consisting of exts. of  
ginseng, Scutellaria root,  
and white birch.

L3 ANSWER 3 OF 11 CAPLUS COPYRIGHT  
2002 ACS

AN 1999:579115 CAPLUS

DN 131:219009

TI Antiaging agents containing clove extracts and  
cosmetics containing the  
extracts

IN Inomata, Shinji; Ota, Masahiro

PA Shiseido Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO. KIND DATE

APPLICATION NO. DATE

PI JP 11246385 A2 19990914 JP 1998-  
67793 19980303

AB Antiaging agents contain solvent exts. of  
Syzygium aromaticum (clove) as

active ingredients. Cosmetics contg. the exts.  
are also claimed.

\*\*\*Clove\*\*\* exts. \*\*\*inhibit\*\*\*  
\*\*\*elastase\*\*\* and maintain

elasticity of skin. Antiwrinkle and elasticity-  
increasing effects of a  
cream foundation contg. an EtOH ext. of clove  
were tested in female  
volunteers.

L3 ANSWER 4 OF 11 CAPLUS COPYRIGHT  
2002 ACS

AN 1961:44010 CAPLUS

DN 55:44010

OREF 55:8569h-i

TI The nature of the elastase inhibitor

AU Viola, S.; Salvini, L.

CS Univ. Florence

SO Giorn. gerontol. (1960), 8, 659-64

DT Journal

LA Unavailable

AB In the serums of 50 human subjects detns.  
were made of serum antielastase

activity by the method of Hall (CA 49, 7611e)

and of serum heparinoids by

the method of S. and V. (CA 51, 1441i). A

direct relation was found

between these levels, the elastase inhibitor

activity increasing at higher

concns. of heparinoids. In parallel with clearing-  
factor activity, the

\*\*\*elastase\*\*\* \*\*\*inhibitor\*\*\* in serum

\*\*\*rose\*\*\* when the

subjects were injected with 100 mg. heparin and

fell slightly after oral

administration of 100 g. butter. The serum

elastase inhibitor may be a

mucopolysaccharide of heparinlike nature.

L3 ANSWER 5 OF 11 WPIDS (C) 2002

THOMSON DERWENT

AN 2001-253773 [26] WPIDS

DNC C2001-076365

TI Cosmetics for improving skin aging, comprises  
component elastase inhibitor

and hydroxy carboxylic acid, ketone carboxylic  
acid, amido derivative,

amine derivative or guanidine derivative.

DC D21

PA (KAOS) KAO CORP

CYC 1

PI JP 2001058920 A 20010306 (200126)\* 11p

ADT JP 2001058920 A JP 1999-233745  
19990820

PRAI JP 1999-233745 19990820

AN 2001-253773 [26] WPIDS

AB JP2001058920 A UPAB: 20010515

NOVELTY - The cosmetics comprises  
component (A) containing

\*\*\*elastase\*\*\* \*\*\*inhibitor\*\*\* such as  
\*\*\*almond\*\*\*, Sanguisorba  
officinalis, \*\*\*clove\*\*\*, Rosae multiflorae  
fructus or Crataegus

oxyacantha and component (B) containing  
hydroxy carboxylic acid, ketone  
carboxylic acid, amido derivative, amine  
derivative or guanidine  
derivative.

USE - As cosmetics for improving skin aging.

ADVANTAGE - The cosmetics effectively  
prevents aging of skin.

Dwg.0/0

L3 ANSWER 6 OF 11 WPIDS (C) 2002

THOMSON DERWENT

AN 1999-424883 [36] WPIDS

DNC C1999-125262

TI Elastase inhibitor - can prevent ageing of skin  
and can be used as

ointment for skin.

DC B04 D21

PA (MARU-N) MARUZEN SEIYAKU KK

CYC 1

PI JP 11171758 A 19990629 (199936)\* 5p

ADT JP 11171758 A JP 1997-362341 19971212

PRAI JP 1997-362341 19971212

AN 1999-424883 [36] WPIDS

AB JP 11171758 A UPAB: 19990908

\*\*\*Elastase\*\*\* \*\*\*inhibitor\*\*\* comprises  
extract of \*\*\*Betula\*\*\*

platy phylla Sukatchev varjaponica,

Cinnamomum cassia Blume, Tilia cordata

Mill, Tilia platyphyllos Scop, Tiliaeuropaea L.

Tilia japonica Simonkai,

Eriobotryajaponica Lindley or Hamamelis  
virginiana L. Extraction is

conducted by using water, methanol or ethanol.

Extract is incorporated in

ointment composition in an amount of 0.01 to 10  
wt %.

ADVANTAGE - The inhibitor can prevent  
aging of skin and can be used  
as ointment for skin.

Dwg.0/0

L3 ANSWER 7 OF 11 WPIDS (C) 2002

THOMSON DERWENT

AN 1999-593870 [51] WPIDS

DNC C1999-173618

TI Elastase inhibitor for skin ageing prevention -  
has active ingredients or

extracts of ginger, hydrolyzing almond, white  
birch and clove.

DC B04 D21

PA (KAOS) KAO CORP; (KAOS) KAO KK

CYC 1

PI JP 2969451 B1 19991102 (199951)\* 4p

JP 2000119189 A 20000425 (200031) 4p

ADT JP 2969451 B1 JP 1998-283981 19981006;

JP 2000119189 A JP 1998-283981

19981006

PRAI JP 1998-283981 19981006

AN 1999-593870 [51] WPIDS

AB JP 2969451 B UPAB: 19991207

NOVELTY - The inhibitor includes active  
ingredients or extracts of ginger,

hydrolyzing almond, Sanguisorba officinalis,

\*\*\*clove\*\*\*, rosae

multiflorae fructus, \*\*\*hawthorn\*\*\* and a

white birch. The

\*\*\*inhibitor\*\*\* exhibits 25% or more of

\*\*\*elastase\*\*\* suppression

activity at a concentration of 5% or less.

USE - For suppressing skin ageing due to  
ultraviolet rays.

ADVANTAGE - Has outstanding elastase  
inhibitory effect and also

excels in safety.

Dwg.0/0

L3 ANSWER 8 OF 11 BIOSIS COPYRIGHT

2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE

AN 1990:418335 BIOSIS  
 DN BA90:79136  
 TI LONG-TERM REPLACEMENT THERAPY IN  
 HOMOZYGOUS ALPHA-1 ANTITRYPSIN  
 DEFICIENCY  
 INFLUENCE ON PROTEINASE  
 ANTIPROTEINASE EQUILIBRIUM IN PLASMA  
 AND SPUTUM.  
 AU BRAUN J; WELLE S; VAN WEES J;  
 WINTERHOFF R; WOOD W G; DALHOFF K;  
 WIESSMANN  
 K-J  
 CS KLINIK FUER INNERE MEDIZIN, ZENTRUM  
 INNERE MEDIZIN DER MEDIZINISCHEN  
 UNIVERSITAET, RATZEBURGER ALLEE 160.  
 SO DMW (DTSCH MED WOCHENSCHR).  
 (1990) 115 (23), 889-894.  
 CODEN: DDMWDF. ISSN: 0012-0472.  
 FS BA; OLD  
 LA German  
 AB Long-term replacement with human .alpha.1-  
 antitrypsin (60 mg/kg once a  
 week intravenously) was carried out in seven  
 patients with homozygous  
 .alpha.1-antitrypsin deficiency (7 males, mean  
 age 50.8 [40-59] years) and  
 progressive pulmonary emphysema for an  
 average of 16 (13-20) weeks. After  
 at least 12 weeks' therapy the concentrations of  
 .alpha.1-antitrypsin,  
 elastase-.alpha.1-antitrypsin complex, .alpha.2-  
 macroglobulin, lactoferrin  
 and elastase inhibition capacity in plasma and  
 sputum were assayed, these  
 assays being performed before starting the  
 .alpha.1-antitrypsin infusion  
 and at various times during the following week.  
 After the infusion the  
 plasma concentration of .alpha.1-antitrypsin  
 rose from a depressed initial  
 level (mean 1.22 g/l) to a level approximately  
 five times higher (median  
 after 1 hour: 5.96 g/l,  $P < 0.001$ ), and then  
 declined exponentially,

though it never fell below the threshold of 35%  
 of normal which is  
 regarded as the protective level. Elastase  
 inhibition capacity displayed  
 similar changes ( $r = 0.85$ ). The sputum  
 concentration of  
 .alpha.1-antitrypsin rose more slowly than the  
 plasma concentration: from  
 the initial lower level (median 8 mg/l) it reached  
 a maximum about four  
 times higher after 24 hours (median 36 mg/l;  $P$   
 $< 0.02$ ). \*\*\*Elastase\*\*\*  
 \*\*\*inhibition\*\*\* capacity \*\*\*rose\*\*\* from 151  
 mIU/ml (median) before  
 the .alpha.1-antitrypsin infusion to 450 mIU/ml  
 at 24 hours. These  
 findings suggest that .alpha.1-antitrypsin  
 replacement will have  
 beneficial effects on proteinase-antiproteinase  
 equilibrium. Determination  
 of elastase inhibition capacity in the sputum is  
 suitable for monitoring  
 dosage during replacement therapy.

L3 ANSWER 9 OF 11 BIOSIS COPYRIGHT  
 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE  
 2

AN 1988:349119 BIOSIS  
 DN BA86:44597  
 TI PLASMA LEVELS OF MAIN GRANULOCYTE  
 COMPONENTS DURING CARDIOPULMONARY  
 BYPASS.  
 AU RIEGEL W; SPILLNER G; SCHLOSSER V;  
 HOERL W H  
 CS MEDIZINISCHE UNIVERSITAETSKLIN.,  
 HUGSTETTERSTR. 55, D-7800 FREIBURG I.BR.,  
 WEST GERMANY.  
 SO J THORAC CARDIOVASC SURG. (1988) 95  
 (6), 1014-1019.  
 CODEN: JTCSAQ. ISSN: 0022-5223.  
 FS BA; OLD  
 LA English  
 AB Plasma levels of granulocyte lactoferrin,  
 myeloperoxidase, and elastase in  
 .alpha.1-proteinase inhibitor complex were  
 compared with C3a and C5a

levels in 10 patients undergoing cardiopulmonary bypass. At the end of the operation, plasma levels of lactoferrin increased from 97.0  $\pm$  22.8 to 1257  $\pm$  139.8 ng/ml, myeloperoxidase increased from 37.1  $\pm$  4.3 to 170.9  $\pm$  34.9 ng/ml, and \*\*\*elastase\*\*\* in .alpha.-proteinase \*\*\*inhibitor\*\*\* complex \*\*\*rose\*\*\* from 89.4  $\pm$  7.4 to 43.78  $\pm$  97.3 ng/ml. There was also a significant anaphylatoxin formation. To investigate the relationship between complement and granulocyte activation, patients undergoing cardiopulmonary bypass received the calcium channel blocker nifedipine (orally and intravenously) and the antiplatelet drug dipyridamole. The continuous infusion of nifedipine (5.91  $\pm$  0.53  $\mu$ g/kg body weight per hour) caused significantly lower levels of elastase in .alpha.-proteinase inhibitor complex and lactoferrin but not anaphylatoxin. Dipyridamole was without effect on complement and granulocyte activation during cardiopulmonary bypass. Our data demonstrate inhibition of granulocyte activation during cardiopulmonary bypass by continuous infusion of nifedipine, even in the presence of complement activation.

L3 ANSWER 10 OF 11 IFIPAT COPYRIGHT 2002 IFI  
 AN 10012522 IFIPAT;IFIUDB;IFICDB  
 TI ANTI-AGING AGENT; PLANT EXTRACT  
 INF Inomata; Shinji, Yokohama-shi, JP  
 IN Inomata Shinji (JP)  
 PAF Unassigned  
 PA Unassigned Or Assigned To Individual (68000)  
 AG Harold C. Wegner FOLEY & LARDNER, Washington Harbour, Suite 500, 3000 K Street, N.W. Washington, DC, 20007-5109, US

PI US 2001012524 A1 20010809

AI US 2001-814220 20010322

RLI US 1998-125786 19980827

CONTINUATION

WO 1997-JP4859 19971225 Section 371

PCT Filing UNKNOWN

PRAI JP 1996-358052 19961227

FI US 2001012524 20010809

DT Utility; Patent Application - First Publication

FS CHEMICAL

FS APPLICATION

CLMN 3

2 Figure(s).

FIG. 1 is a graph showing the \*\*\*elastase\*\*\* \*\*\*inhibiting\*\*\* activity of an Uncaria \*\*\*gambir\*\*\* Roxburgh extract in comparison with fetal calf serum.  
 FIG. 2 shows the \*\*\*elastase\*\*\* \*\*\*inhibiting\*\*\* activity at low concentration of Uncaria \*\*\*gambir\*\*\* Roxburgh extract.

AB This invention relates to an anti-aging agent, more particularly, it relates to an anti-aging agent having an elastase inhibiting action and capable of maintaining the tautness and elasticity of the skin and maintaining a youthful state of the skin. According to the present invention, there is provided an antiaging agent containing, as an effective ingredient, a solvent extract of Uncaria gambir Roxburgh.

CLMN 3 2 Figure(s).

FIG. 1 is a graph showing the \*\*\*elastase\*\*\* \*\*\*inhibiting\*\*\* activity of an Uncaria \*\*\*gambir\*\*\* Roxburgh extract in comparison with fetal calf serum.  
 FIG. 2 shows the \*\*\*elastase\*\*\* \*\*\*inhibiting\*\*\* activity at low concentration of Uncaria \*\*\*gambir\*\*\* Roxburgh extract.

L3 ANSWER 11 OF 11 SCISEARCH  
 COPYRIGHT 2002 ISI (R)  
 AN 91:237535 SCISEARCH  
 GA The Genuine Article (R) Number: FE985  
 TI REPLACEMENT THERAPY WITH ALPHA-1-  
 PROTEINASE-INHIBITOR IN PATIENTS WITH  
 HOMOZYGOUS ALPHA-1-ANTITRYPSIN  
 DEFICIENCY  
 AU BRAUN J (Reprint); WELLE S; WOOD W G;  
 DALHOFF K; WIESSMANN K J  
 CS MED UNIV LUBECK, INNERE MED KLIN,  
 RATZEBURGER ALLEE 160, W-2400 LUBECK,  
 GERMANY (Reprint)  
 CYA GERMANY  
 SO ATEMWEGS-UND LUNGENKRANKHEITEN,  
 (1990) Vol. 16, No. 7, pp. 303-305.  
 DT Article: Journal  
 LA German  
 REC Reference Count: 9  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND  
 IALL FORMATS\*  
 AB Long-term replacement therapy with human  
 alpha-1-proteinase inhibitor  
 (60 mg/kg i.v. once weekly) was carried out in 9  
 patients with homozygous  
 alpha-1-antitrypsin deficiency and progressive  
 pulmonary emphysema. The  
 concentration of alpha-1-proteinase inhibitor  
 and the elastase-inhibition  
 capacity (EIC) were assayed in plasma and  
 sputum before  
 alpha-1-PI-infusion and at various times during  
 the following week. After  
 the infusion the plasma concentration of alpha-  
 1PI rose from a depressed  
 initial level (median 1.22 g/l) to a level  
 approximately five times higher  
 (median after 1 hour: 5.96 g/l;  $p < 0.001$ ), and  
 then declined  
 exponentially. Elastase-inhibition capacity  
 displayed similar changes ( $r$   
 = 0.85). In sputum the concentration of alpha-  
 1PI rose more slowly than  
 the plasma concentration; from the initial level  
 (median 8 mg/l) it

reached a maximum about four times higher  
 after 24 hours (median 36 mg/l;  
 $p < 0.02$ ). \*\*\*Elastase\*\*\* - \*\*\*inhibition\*\*\*  
 capacity \*\*\*rose\*\*\*  
 from 151 mIU/ml (median) before alpha-1PI-  
 infusion to 450 mIU/ml at 24  
 hours. These findings suggest that replacement  
 with alpha-1PI has a  
 beneficial effect on proteinase-antiproteinase-  
 equilibrium. The  
 determination of the elastase-inhibition capacity  
 in sputum is suitable  
 for monitoring dosage during replacement  
 therapy.

=> file stnguide  
 COST IN U.S. DOLLARS                      SINCE  
 FILE    TOTAL

ENTRY  
 SESSION  
 FULL ESTIMATED COST  
 56.69    64.85

DISCOUNT AMOUNTS (FOR QUALIFYING  
 ACCOUNTS)    SINCE FILE    TOTAL  
 ENTRY

SESSION  
 CA SUBSCRIBER PRICE                      -  
 2.48    -2.48

FILE 'STNGUIDE' ENTERED AT 08:55:30 ON 06  
 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR  
 CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL  
 SOCIETY, JAPAN SCIENCE  
 AND TECHNOLOGY CORPORATION, AND  
 FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Aug 2, 2002 (20020802/UP).

=> log y  
 COST IN U.S. DOLLARS                      SINCE  
 FILE    TOTAL



ENTRY

SESSION

FULL ESTIMATED COST

1.26 66.11

DISCOUNT AMOUNTS (FOR QUALIFYING  
ACCOUNTS) SINCE FILE TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00 -2.48

STN INTERNATIONAL LOGOFF AT 09:08:08 ON  
06 AUG 2002